13F Holdings
中文EN

CRIS CURIS INC

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1108205 · Fiscal year ends 12/31

Financial factors as of 2026-03-31 (2026Q1), TTM = sum of the last four quarters

Growth

TTM revenue YoY-36.9%
TTM net income YoY49.8%
TTM EPS YoY90.5%
Revenue 3-yr CAGR-12.1%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-100.2%
Net margin-299.7%
FCF margin—
EBITDA margin-98.5%

Returns

ROE-693.9%
ROA-61.3%
ROIC (approx.)—
Asset turnover0.20x

Leverage & solvency

Liabilities / assets57.2%
Debt / equity0.00x
Current ratio1.11x
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.37x
Accruals ratio22.6%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$9.44M$10.91M$10.02M$10.16M$10.65M
R&D expense$28.25M$38.56M$39.50M$43.28M$34.88M
SG&A expense$14.05M$16.79M$18.65M$19.65M$17.30M
Operating income-$5.71M-$44.54M-$48.33M-$53.02M-$42.06M
Interest expense————$0
Income tax$0$0———
Net income-$7.58M-$43.39M-$47.41M-$56.67M-$45.44M
EBITDA-$5.54M-$44.34M-$48.08M-$52.79M-$41.91M
EPS (basic)-0.58-6.88-8.96-12.140.50
EPS (diluted)-0.58-6.88-8.96-12.140.50
Weighted avg. shares (diluted)13.16M6.31M5.29M4.67M91.57M
Balance sheet
Cash & equivalents$5.06M$20.54M$27.23M$20.29M$40.74M
Short-term investments—$0$29.65M$65.97M$75.87M
Receivables$0$3.35M$2.79M$2.98M$3.22M
Current assets$6.92M$26.39M$60.91M$92.12M$122.38M
PP&E, net$62,000$231,000$434,000$689,000$505,000
Goodwill$8.98M$8.98M$8.98M$8.98M$8.98M
Total assets$19.97M$41.27M$77.28M$108.85M$162.30M
Current liabilities$14.08M$19.03M$22.02M$10.01M$13.44M
Short-term debt$0$7.56M$8.50M—$0
Total liabilities$14.50M$47.26M$57.61M$62.30M$71.59M
Shareholders' equity$5.46M-$6.00M$19.67M$46.55M$90.71M
Shares outstanding646,5378.49M5.89M4.83M91.65M
Cash flow statement
Operating cash flow-$27.20M-$39.56M-$38.43M-$54.34M-$37.62M
Capital expenditure——$0$416,000$0
Free cash flow——-$38.43M-$54.75M-$37.62M
Investing cash flow$2.50M$29.44M$37.79M$33.02M-$47.90M
Financing cash flow$9.77M$3.44M$7.58M$867,000-$4.17M
Depreciation & amortization$169,000$203,000$255,000$233,000$158,000
Stock-based compensation$4.02M$5.93M$6.00M$6.75M$5.28M

Free plan shows the latest 5 periods; Pro shows all 17 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.